

HEDIS® MEASURE

Initiation and Engagement of Substance Use Disorder Treatment (IET)



Measure Overview


The NCQA HEDIS® Initiation and Engagement of Substance Use Disorder Treatment (IET) measure looks at the percentage of new substance use disorder (SUD) episodes that result in treatment initiation and engagement. Two rates are reported:

- **Initiation of SUD treatment.** The percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth visit or medication treatment within 14 days.
- **Engagement of SUD treatment.** The percentage of new SUD episodes that have evidence of treatment engagement within 34 days of initiation.

Required Exclusions:

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who died during the measurement year.

IET at a Glance



Ways to Improve Measure Performance

- Provide timely submission of claims and code substance related diagnosis.
- Use correct HEDIS® compliant codes when billing for the initiation and engagement treatment.
- Schedule follow-up visits within 14 days and at least two additional visits within 34 days of initiation or refer immediately to a behavioral health provider when giving a diagnosis of alcohol or other drug dependence.
- Send appointment reminder 72 hours prior to follow-up appointment. A **telephone and/or telehealth** appointment within the required timeframe meets criteria for an engagement visit.
- Utilize telehealth and home-based therapy where appropriate.
- Discuss the importance of timely, recommended follow-up visits.
- Reach out to members who cancel appointments and assist them with rescheduling as soon as possible.

Description of Criteria

Description	Criteria
Alcohol Abuse and Dependence	ICD-10: F10.10, F10.120, F10.121, F10.129-F10.132, F10.139, F10.14, F10.150, F10.151, F10.159, F10.180-F10.182, F10.188, F10.19, F10.20, F10.220, F10.221, F10.229-F10.232, F10.239, F10.24, F10.250, F10.251, F10.259, F10.26, F10.27, F10.280-F10.282, F10.288, F10.29
Opioid Abuse and Dependence	ICD-10: F11.10, F11.120-F11.122, F11.129, F11.13, F11.14, F11.150, F11.151, F11.159, F11.181, F11.182, F11.188, F11.19, F11.20, F11.220-F11.222, F11.229, F11.23, F11.24, F11.250, F11.251, F11.259, F11.281, F11.282, F11.288, F11.29
Other Drug Abuse and Dependence	ICD-10: F12.10, F12.120-F12.122, F12.129, F12.13, F12.150, F12.151, F12.159, F12.180, F12.188, F12.19, F12.20, F12.220-F12.222, F12.229, F12.23, F12.250, F12.251, F12.259, F12.280, F12.288, F12.29, F13.10, F13.120, F13.121, F13.129-F13.132, F13.139, F13.14, F13.150, F13.151, F13.159, F13.180-F13.182, F13.188, F13.19, F13.20, F13.220, F13.221, F13.229-F13.232, F13.239, F13.24, F13.250, F13.251, F13.259, F13.26, F13.27, F13.280-F13.282, F13.288, F13.29, F14.10, F14.120-F14.122, F14.129, F14.13, F14.14, F14.150, F14.151, F14.159, F14.180-F14.182, F14.188, F14.19, F14.20, F14.220-F14.222, F14.229, F14.23, F14.24, F14.250, F14.251, F14.259, F14.280-F14.282, F14.288, F14.29, F15.10, F15.120-F15.122, F15.129, F15.13, F15.14, F15.150, F15.151, F15.159, F15.180- F15.182, F15.188, F15.19, F15.20, F15.220-F15.222, F15.229, F15.23, F15.24, F15.250, F15.251, F15.259, F15.280-F15.282, F15.288, F15.29, F16.10, F16.120-F16.122, F16.129, F16.14, F16.150, F16.151, F16.159, F16.180, F16.183, F16.188, F16.19, F16.20, F16.220, F16.221, F16.229, F16.24, 16.250, F16.251, F16.259, F16.280, F16.283, F16.288, F16.29, F18.10, F18.120, F18.121, F18.129, F18.14, F18.150, F18.151, F18.159, F18.17, F18.180, F18.188, F18.19, F18.20, F18.220, F18.221, F18.229, F18.24, F18.250, F18.251, F18.259, F18.27, F18.280, F18.288, F18.29, F19.10, F19.120-

	F19.122, F19.129-F19.132, F19.139, F19.14, F19.150, F19.151, F19.159, F19.16, F19.17, F19.180, F19.181, F19.182, F19.188, F19.19, F19.20, F19.220-F19.222, F19.229-F19.232, F19.239, F19.24, F19.250, F19.251, F19.259, F19.26, F19.27, F19.280-F19.282, F19.288, F19.29
BH Outpatient Visit	CPT: 98960-98962, 99078, 99202-99205, 99211-99215, 99242-99245, 99341, 99342, 99344, 99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510 HCPCS: G0155, G0176, G0177, G0409, G0463, G0512, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010, H2011, H2013-H2020, T1015 UBREV: 0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0900, 0902-0904, 0911, 09140917, 0919, 0982, 0983
Partial Hospitalization or Intensive Outpatient	CPT Visit Setting Unspecified: 90791-90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875-90876, 99221-99223, 99231-99233, 99238-99239, 99252-99255 with POS: 52 HCPCS Partial Hospitalization: G0410-G0411, H0035, H2001, H2012, S0201, S9480, S9484-S9485 UBREV: 0905, 0907, 0912, 0913
Visit Setting Unspecified	CPT: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99252-99255 with Outpatient POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72 or with Partial Hospitalization POS: 52 or with Non-residential Substance Abuse Treatment Facility POS: 57, 58 or with Community Mental Health Center POS: 53 or with Telehealth POS: 02, 10
Substance Use Disorder Service or Substance Abuse Counseling and Surveillance	CPT: 99408, 99409 HCPCS: G0396, G0397, G0443, H0001, H0005, H0007, H0015, H0016, H0022, H0047, H0050, H2035, H2036, T1006, T1012 UBREV: 0906, 0944, 0955 ICD-10: Z71.41, Z71.51
Opioid Treatment Services	UD Weekly Non-Drug Service HCPCS: G2071, G2074, G2075, G2076, G2077, G2080 UD Weekly Drug Treatment Service HCPCS: G2067, G2068, G2069, G2070, G2072, G2073 UD Monthly Office Based Treatment HCPCS: G2086, G2087
Telephone Visits	CPT: 98966-98968, 99441-99443
Online Assessments (E-visits or Virtual Check-in)	CPT: 98970-98972, 98980, 98981, 99421-99423, 99457, 99458 HCPCS: G0071, G2010, G2012, G2250-G2252
Opioid Treatment	HCPCS: Weekly Treatment: G2067-2077 Monthly Treatment: G2086, G2087

Medications

Alcohol Use Disorder Treatment Medications

Description	Prescription
Aldehyde Dehydrogenase Inhibitor	Disulfiram (Oral)

Antagonist	Naltrexone (Oral and Injectable)
Other	Acamprosate (Oral; Delayed-Release Tablet)

Opioid Use Disorder Treatment Medications

Description	Prescription
Antagonist	Naltrexone (Oral and Injectable)
Partial Agonist	Buprenorphine (Sublingual Tablet, Injection, And Implant), Buprenorphine/Naloxone (Sublingual Tablet, Buccal Film, Sublingual Film)